Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Author:
Affiliation:
1. Division of Cardiology; Los Angeles Biomedical Research Institute; Torrance CA USA
2. Obesity and Endocrinology Clinical Research; Institute of Ageing and Chronic Disease; University of Liverpool; Liverpool UK
Funder
Janssen Scientific Affairs, LLC
Publisher
Hindawi Limited
Subject
General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/ijcp.12948/fullpdf
Reference114 articles.
1. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors;Wannamethee;Arch Intern Med,2011
2. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies;Huxley;BMJ,2006
3. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations;Low Wang;Circulation,2016
4. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials;Inzucchi;Diab Vasc Dis Res,2015
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus;Advanced Therapeutics;2023-09-28
2. Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement;Current Molecular Pharmacology;2023-08
3. Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function;European Journal of Pharmacology;2023-06
4. Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure;Journal of Pharmacological Sciences;2022-12
5. Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus;Journal of the Pakistan Medical Association;2022-06-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3